Found: 4
Select item for more details and to access through your institution.
666-P: Greater Proportions of Subjects Achieved HbA1c <7% without Weight Gain, Hypoglycemia, or Moderate/Severe Gastrointestinal Adverse Events with Semaglutide vs. Comparators in the SUSTAIN 7-10 Trials.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-666-P
- By:
- Publication type:
- Article
Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)
- Published in:
- Urolithiasis, 2023, v. 51, n. 1, p. 1, doi. 10.1007/s00240-023-01453-3
- By:
- Publication type:
- Article
Correction to: Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4).
- Published in:
- Urolithiasis, 2023, v. 51, n. 1, p. 1, doi. 10.1007/s00240-023-01453-3
- By:
- Publication type:
- Article